sub:assertion {
<
http://purl.obolibrary.org/obo/DOID_1040>
bl:category bl:Disease .
sub:association rdf:object <
http://purl.obolibrary.org/obo/DOID_1040> ;
rdf:predicate bl:treats ;
rdf:subject <
https://identifiers.org/drugbank:DB09053> ;
a rdf:Statement ;
rdfs:label "imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 1 1 chronic lymphocytic leukemia cll small lymphocytic lymphoma sll 1 2 chronic lymphocytic leukemia cll small lymphocytic lymphoma sll with 17p deletion 1 3 waldenstrom s macroglobulinemia wm 1 4 marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anti cd2 based therapy 1 5 chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 1 6 imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy accelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 14 1 imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll small lymphocytic lymphoma sll imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll small lymphocytic lymphoma sll with 17p deletion imbruvica is indicated for the treatment of adult patients with waldenstrom s macroglobulinemia wm imbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anti cd2 based therapy accelerated approval was granted for this indication based on overall response rate see clinical studies 14 4 imbruvica is indicated for the treatment of adult patients with chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy" ;
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
bl:provided_by <
https://w3id.org/um/NeuroDKG> ;
bl:relation schema:TreatmentIndication .
<
https://identifiers.org/drugbank:DB09053>
bl:category bl:Drug .
}